The second study consisted of a larger sample size (n = 185) and was consistent with the first study: Sel-Cap detected over two-thirds of EGFR-activating mutations that were detected by PNAclamp in tumor (sensitivity: 72% for Ex19del and 67% for L858R). Here, EGFR is linked to neoplasm.